TechCrunch Startup News Science Corp raises $230M as it races to bring its brain implant to market
Mar 5, 2026
A deep dive into a $230M funding round that pushes a brain implant toward market. Discussion of a rice-sized retinal implant and its potential to restore reading for macular degeneration. Trial results across dozens of patients and planned regulatory paths in Europe and the U.S. Exploration of additional neural interface and organ preservation research funded by the raise.
AI Snips
Chapters
Transcript
Episode notes
Prima Implant Restores Functional Reading Vision
- Science Corp targets Prima, a rice-grain implant that with camera glasses restores functional vision in advanced macular degeneration patients.
- Trials across 47 patients showed 80% meaningful visual acuity improvement, with patients able to read letters, numbers, and words.
Science Corp Bought And Completed Pixium's Prima Trials
- Science Corp acquired Prima's assets from Pixium Vision in 2024 and completed the trials Pixium had started.
- Max Hodak highlighted that this may be the first definitive restoration of fluent reading in blind patients.
Regulatory Push Could Make Science Corp First BCI On Market
- Science Corp has submitted a CE mark application and expects EU approval by mid-year, aiming to launch first in Europe with Germany likely first.
- The company claims this timeline could make it the first BCI company to have a market product.